MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sorrento Therapeutics Company Profile (NASDAQ:SRNE)

Consensus Ratings for Sorrento Therapeutics (NASDAQ:SRNE) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.00 (398.22% upside)

Analysts' Ratings History for Sorrento Therapeutics (NASDAQ:SRNE)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016FBR & Co.Lower Price TargetOutperform$21.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015HC WainwrightInitiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/3/2015MLV & Co.Initiated CoverageBuy$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2014AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Sorrento Therapeutics (NASDAQ:SRNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.32)($0.27)$1.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/18/2014($0.34)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/23/2014($0.29)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Sorrento Therapeutics (NASDAQ:SRNE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.52)($0.37)($0.45)
Q2 20161($0.15)($0.15)($0.15)
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)
Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Sorrento Therapeutics (NASDAQ:SRNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2015Henry JiCEOBuy500$0.95$475.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Sorrento Therapeutics (NASDAQ:SRNE)
DateHeadline
06/24/16 06:37 PMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 06:36 PMRecently Issued Stock Ratings For Sorrento Therapeutics, Inc. (SRNE) - Fiscal Standard
06/24/16 04:28 PMBRIEF-Frejoy Investment Management reports 9.2 pct passive stake in Sorrento Therapeutics - * Frejoy Investment Management Co Ltd reports 9.2 percent passive stake in Sorrento Therapeutics Inc as of june 7, 2016 - SEC filing Source text: http://1.usa.gov/28TiETY Further company coverage:...
06/21/16 06:03 PMInvestor News: Investigation over potential Wrongdoing at Sorrento Therapeutics Inc (NASDAQ:SRNE)
06/20/16 08:02 AMInvestor News: Investigation over potential Wrongdoing at Sorrento Therapeutics Inc (NASDAQ:SRNE) - GroundReport
06/15/16 06:27 PMSorrento Therapeutics, Inc. (SRNE) Updated Price Targets - FTSE News
06/14/16 06:13 PMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Yearly Sales Estimate At $145.571 - Investor Newswire
06/13/16 09:33 AMInvestigation for Investors Who Hold Shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) Announced
06/08/16 06:08 AMSorrento Closes $150 Million Private Placement Investments - [at noodls] - SAN DIEGO, June 8, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; 'Sorrento'), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other ...
06/07/16 06:50 PMSorrento Therapeutics Signs Deal with Chinese Pharmaceutical Co.
06/07/16 08:18 AMSorrento and 3SBio Announce CAR-T Joint Venture in China - [at noodls] - SAN DIEGO, June 7, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ('Sorrento'), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other ...
06/06/16 03:50 PMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi -
06/04/16 09:34 AMSorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Growing Impatient With Lack of Disclosure, Repeats ... - Insider Monkey (blog)
06/03/16 08:19 PMSorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Growing Impatient With Lack of Disclosure, Repeats Demands -
06/03/16 07:13 PMStock Review and Earnings Check on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - HNN
06/01/16 09:34 AMTarget Price and Stock Performance Rundown for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - HNN - Target Price and Stock Performance Rundown for Sorrento Therapeutics, Inc. (NASDAQ:SRNE)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Sorrento Therapeutics, Inc.and more »
05/31/16 06:58 PMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Stock Update & Estimates - Stock Tick Tock - Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to post earnings of $-0.14 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
05/28/16 10:02 AMEarnings Review and Stock Rundown for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Wall Street Hints and News - Earnings Review and Stock Rundown for Sorrento Therapeutics, Inc. (NASDAQ:SRNE)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Sorrento Therapeutics, Inc. (NASDAQ:SRNE ...and more »
05/26/16 10:11 AMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Reports Yearly Sales Estimate At $145.57 - Investor Newswire - Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Reports Yearly Sales Estimate At $145.57Investor NewswireAs many as 2 analysts reported that average annual sales estimate for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) stands at $145.57 and the median is $145.57 for the period closed 4. The lowest sales forecast is $54 and the highest sales estimate is ...and more »
05/26/16 10:11 AMBroker Roundup For Sorrento Therapeutics, Inc. (SRNE) - Share Trading News - Broker Roundup For Sorrento Therapeutics, Inc. (SRNE)Share Trading News11/20/2013 – CRT Capital began new coverage on Sorrento Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 11 price target on the stock. The share price of Sorrento Therapeutics, Inc. (SRNE) was up +1.53% during the last trading ...and more »
05/26/16 06:17 AMSorrento Therapeutics to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - SAN DIEGO, May 26, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; 'Sorrento'), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other ...
05/24/16 02:42 PMETF’s with exposure to Sorrento Therapeutics, Inc. : May 24, 2016 -
05/23/16 12:24 PMSorrento Therapeutics, Inc. :SRNE-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/19/16 12:04 PMSORRENTO THERAPEUTICS, INC. Financials -
05/19/16 11:17 AMSorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Files a Complaint -
05/16/16 09:43 AMSorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Ups Its Stake and Reiterates Demands -
05/16/16 06:32 AMSorrento Announces Positive Data from a Combined Phase 2 & 3 Clinical Study of STI-004, an Anti-IgE Biosimilar Antibody - [at noodls] - SAN DIEGO, May 16, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; 'Sorrento'), an antibody-centric, clinical-stage biopharmaceutical company developing new therapies for cancer and other ...
05/10/16 05:13 AMSORRENTO THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/09/16 11:58 AMSorrento Therapeutics engaged advisors for exploring strategic alternatives - [at noodls] - SAN DIEGO, May 9, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; 'Sorrento'), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other ...
03/14/16 01:06 PMChanges To Broker Targets On Sorrento Therapeutics, Inc. (SRNE) - Share Trading News - Changes To Broker Targets On Sorrento Therapeutics, Inc. (SRNE)Share Trading News11/20/2013 – CRT Capital began new coverage on Sorrento Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 11 price target on the stock. The share price of Sorrento Therapeutics, Inc. (SRNE) was up +0.87% during the last trading ...and more »
03/14/16 06:00 AMSorrento to Present at the 28th Annual ROTH Conference - [PR Newswire] - SAN DIEGO, March 14, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today ...
03/04/16 06:00 AMSorrento to Present at the Cowen and Company 36th Annual Health Care Conference - [PR Newswire] - SAN DIEGO, March 4, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today ...
03/02/16 02:59 PMNoteworthy Wednesday Option Activity: SRNE, GMCR, FB - Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sorrento Therapeutics Inc (NASD: SRNE), where a total of 1,807 contracts have traded so far, representing approximately 180,700 underlying shares.
03/02/16 08:59 AMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Other Events -
03/02/16 06:00 AMYuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia - [PR Newswire] - Yuhan), one of the largest and most respected pharmaceutical companies in South Korea, today announced that they have entered into an agreement to form a joint venture company (JVC), ImmuneOncia Therapeutics, LLC, to develop and commercialize a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors. A recent report has predicted that the annual market for immunotherapies, consisting of anti-checkpoint antibodies, vaccines, and cell therapies, will exceed $35B while becoming the backbone of treatment for up to 60% of cancers over the next decade.1 ImmuneOncia will benefit from Sorrento's leading immunotherapy product portfolio as well as its manufacturing capabilities. The joint venture will also take advantage of Yuhan's world-class experience in research and development.
02/26/16 10:53 AMSorrento Therapeutics (NASDAQ:SRNE) Short Interest Update - The Sussex Pilot - Sorrento Therapeutics (NASDAQ:SRNE) Short Interest UpdateThe Sussex PilotOn a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Sorrento Therapeutics, Inc., Ji Henry had purchased ...
02/26/16 10:53 AMIs Buying Sorrento Therapeutics Inc Here a Winning Strategy? - Business Standard Tribune - Is Buying Sorrento Therapeutics Inc Here a Winning Strategy?Business Standard TribuneThe stock of Sorrento Therapeutics Inc (NASDAQ:SRNE) is a huge mover today! The stock increased 5.01% or $0.3 during the last trading session, hitting $6.29. About 292,752 shares traded hands. Sorrento Therapeutics Inc (NASDAQ:SRNE) has declined ...
02/21/16 01:54 PMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Makes Place In Top Stocks - Stocks Daily - Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Makes Place In Top StocksStocks DailyZacks Group, a renowned entity in the market, planned a survey of sell-side experts. Going by this survey, Sorrento Therapeutics, Inc. (NASDAQ:SRNE) was assigned 1 rating. Zacks has a scale of 1 to 5 on which it assigns ratings to companies' stocks.Brokerages Set Sorrento Therapeutics Inc (NASDAQ:SRNE) PT at $29.33Intercooler FinancialSorrento Therapeutics, Inc. (NASDAQ:SRNE): Sell-Side Analysts View on EarningsUptick AnalystWhat's Hot Today: Transocean Partners LLC (NYSE:RIGP), Sorrento Therapeutics, Inc. (NASDAQ:SRNE), M/I Homes ...Stock TranscriptRiversideGazette.comall 5 news articles »
02/11/16 01:57 PMWhat's Next for Sorrento Therapeutics Inc After Today's Huge Decline? - Sonoran Weekly Review - What's Next for Sorrento Therapeutics Inc After Today's Huge Decline?Sonoran Weekly ReviewThe stock of Sorrento Therapeutics Inc (NASDAQ:SRNE) is a huge mover today! The stock is down 6.00% or $0.3 after the news, hitting $4.7 per share. About 318,529 shares traded hands. Sorrento Therapeutics Inc (NASDAQ:SRNE) has declined 71.08% ...and more »
02/05/16 03:00 PMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits -
01/30/16 12:00 PMAnalyst Price Target on Sorrento Therapeutics, Inc. - Market Briefing - Analyst Price Target on Sorrento Therapeutics, Inc.Market BriefingSorrento Therapeutics, Inc. (NASDAQ:SRNE): The stock price is expected to reach $ 24.25 in the short term. The number of analysts agreeing with this consensus is 4. The higher estimate for the short term price target is at $45 while the lower estimate ...
01/28/16 07:00 AMOncBioMune Patents a New Promising Approach to Chemotherapy - [Accesswire] - REDONDO BEACH, CA / ACCESSWIRE / January 28, 2016 / Chemotherapy compounds like paclitaxel and docetaxel have been used for years to treat cancer, but the caveat is that they indiscriminately kill both ...
01/25/16 11:42 AMCompany Shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Rally 2.87% - WallStreet Prudent - Company Shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Rally 2.87%WallStreet PrudentShares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) appreciated by 2.87% during the past week but lost 35.24% on a 4-week basis. The shares have outperformed the S&P 500 by 1.43% in the past week but underperformed the index by 30.01% in the last ...and more »
01/20/16 11:25 AMPrice Target Update On Sorrento Therapeutics, Inc. (SRNE) - Risers & Fallers - Price Target Update On Sorrento Therapeutics, Inc. (SRNE)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Sorrento Therapeutics, Inc. (SRNE). According to the latest broker reports 2 analysts have a rating of “buy”, 3 analysts “outperform”, 0 analysts “hold”, 0 analysts ...and more »
01/11/16 01:52 PMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
01/11/16 06:27 AMSorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002 - [at noodls] - SAN DIEGO, Jan. 11, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other ...
01/11/16 05:07 AMSorrento and Karolinska Institutet Establish Exclusive Partnership for Research and Development of Natural Killer Cell-based Therapies - [at noodls] - SAN DIEGOand STOCKHOLM, Jan. 11, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer ...
01/08/16 06:15 AMUpcoming Corporate Presentations In San Francisco - [at noodls] - SAN DIEGO, Jan. 8, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain, announced today ...
01/05/16 07:48 AMSorrento Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 -
12/23/15 07:07 AMSorrento Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : December 23, 2015 -
About Sorrento Therapeutics

Sorrento Therapeutics logoSorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SRNE
  • CUSIP:
Key Metrics:
  • Previous Close: $5.62
  • 50 Day Moving Average: $6.20
  • 200 Day Moving Average: $6.41
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $225.99M
  • Current Quarter EPS Consensus Estimate: $-0.85 EPS
Additional Links:
Sorrento Therapeutics (NASDAQ:SRNE) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha